Lixin Biological

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement with Guangzhou Lixin Biological Technology Co., Ltd. concerning the drug candidate ACC006. Initially inked in December 2021, the agreement saw Aidea Pharma bestow upon Lixin Bio the rights to its cancer drug candidate ACC006 for…